« Previous  |  Next »

CORRESPONDENCE: Home Blood-Pressure Monitoring in Patients Receiving Sunitinib

. To the Editor: The use of sunitinib, an inhibitor of the split-kinase-domain family of receptor tyrosine kinases (including vascular endothelial growth factor receptor types 1 and 21), has been associated with a 15 to 25% incidence of ...

From AZIZI, M., CHEDID, A., OUDARD, S., New England Journal of Medicine -- Recent Issues,  2 Jan 2008

« Previous  |  Next »

Who is This?

Help us add to our database, by linking this writer their entry in Wikipedia or Source Watch, or by suggesting that we remove it from our index.

Suggest an Entry